S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
Log in

NYSE:IQVIqvia Stock Price, Forecast & News

$125.46
+5.78 (+4.83 %)
(As of 04/8/2020 03:08 PM ET)
Add
Compare
Today's Range
$117.67
Now: $125.46
$125.57
50-Day Range
$84.00
MA: $125.82
$165.42
52-Week Range
$81.79
Now: $125.46
$169.14
Volume103,469 shs
Average Volume2.95 million shs
Market Capitalization$24.13 billion
P/E Ratio129.34
Dividend YieldN/A
Beta1.12
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Read More
Iqvia logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
CUSIPN/A
Phone919-998-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.09 billion
Cash Flow$15.12 per share
Book Value$32.28 per share

Profitability

Net Income$191 million

Miscellaneous

Employees67,000
Market Cap$24.13 billion
Next Earnings Date4/28/2020 (Confirmed)
OptionableOptionable

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.


Iqvia (NYSE:IQV) Frequently Asked Questions

How has Iqvia's stock been impacted by COVID-19 (Coronavirus)?

Iqvia's stock was trading at $125.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IQV stock has increased by 0.0% and is now trading at $125.46. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Iqvia?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iqvia.

When is Iqvia's next earnings date?

Iqvia is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Iqvia.

How can I listen to Iqvia's earnings call?

Iqvia will be holding an earnings conference call on Tuesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) released its quarterly earnings data on Wednesday, February, 12th. The medical research company reported $1.74 EPS for the quarter, topping the Zacks' consensus estimate of $1.72 by $0.02. The medical research company had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.85 billion. Iqvia had a net margin of 1.72% and a return on equity of 17.65%. Iqvia's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period last year, the firm posted $1.50 EPS. View Iqvia's earnings history.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia issued an update on its first quarter earnings guidance on Friday, April, 3rd. The company provided EPS guidance of $1.46-1.51 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.59. The company issued revenue guidance of $2.71-2.74 billion, compared to the consensus revenue estimate of $2.81 billion.

What price target have analysts set for IQV?

17 equities research analysts have issued twelve-month price targets for Iqvia's shares. Their forecasts range from $110.00 to $200.00. On average, they anticipate Iqvia's share price to reach $153.81 in the next year. This suggests a possible upside of 22.6% from the stock's current price. View analysts' price targets for Iqvia.

Has Iqvia been receiving favorable news coverage?

News headlines about IQV stock have been trending very negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iqvia earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutIqvia.

Are investors shorting Iqvia?

Iqvia saw a decline in short interest in March. As of March 13th, there was short interest totaling 2,777,500 shares, a decline of 22.2% from the February 27th total of 3,570,000 shares. Based on an average daily volume of 1,500,000 shares, the short-interest ratio is presently 1.9 days. Approximately 1.5% of the shares of the company are sold short. View Iqvia's Current Options Chain.

Who are some of Iqvia's key competitors?

What other stocks do shareholders of Iqvia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Allergan (AGN) and salesforce.com (CRM).

Who are Iqvia's key executives?

Iqvia's management team includes the following people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Who are Iqvia's major shareholders?

Iqvia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include McGuire Investment Group LLC (0.05%), State of Alaska Department of Revenue (0.04%), Gradient Investments LLC (0.02%), Callahan Advisors LLC (0.01%), Buffington Mohr McNeal (0.01%) and Foundations Investment Advisors LLC (0.00%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View institutional ownership trends for Iqvia.

Which major investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Buffington Mohr McNeal, McGuire Investment Group LLC, Callahan Advisors LLC, and Global Trust Asset Management LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Kevin C Knightly, Michael J Evanisko, and Michael R Mcdonnell. View insider buying and selling activity for Iqvia.

Which major investors are buying Iqvia stock?

IQV stock was acquired by a variety of institutional investors in the last quarter, including Gradient Investments LLC, State of Alaska Department of Revenue, IBM Retirement Fund, and Foundations Investment Advisors LLC. View insider buying and selling activity for Iqvia.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $125.46.

How big of a company is Iqvia?

Iqvia has a market capitalization of $24.13 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe. View additional information about Iqvia.

What is Iqvia's official website?

The official website for Iqvia is http://www.iqvia.com/.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: Resistance Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel